BackDeep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Overview

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Accounts Payable

Latest accounts payable for DMAQU: $3.2M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$3.25M
1.23% YoYΔ $39373.00 vs prior year quarter

Peer trimmed avg / median

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Accounts Payable History

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) vs. peers: Accounts Payable Comparison

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) (DMAQU) FAQ

The latest accounts payable for DMAQU is $3.2M as of June 2026. That compares with $3.2M in the prior-year period — up 1.2% year over year. Investors often review this figure alongside Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, DMAQU's accounts payable moved from $3.2M to $3.2M — a 1.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right)'s operating scale or balance-sheet position.

A accounts payable figure of $3.2M for DMAQU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DMAQU's accounts payable ($3.2M), review year-over-year change from $3.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.